A Phase 3 interventional study of Irinotecan liposome injection and Topotecan in Small Cell Lung Cancer, sponsored by Ipsen. Completed at 118 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-19.
Sponsored by Ipsen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 629 studies in Small Cell Lung Carcinoma with a site in United States — 111 open to participants now, 182 under way, 26 of them phase 3. Small Cell Lung Carcinoma · United States.
Among the 629 studies in Small Cell Lung Carcinoma with a site in United States, this one is the 45th largest by enrollment of the 550 interventional ones that give a count, is one of 33 that started in 2018, is one of 50 in phase 3, and was the 337th registered.
1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.
Browse Small Cell Lung Carcinoma studies →111 of the 629 studies in Small Cell Lung Carcinoma with a site in United States are open now. Recruiting first, the newest first:
Misty Shields · Sites in United States
Ages 18+
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+
Boehringer Ingelheim · Sites in United States, Australia, Belgium and 8 more countries
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Jazz Pharmaceuticals · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
629 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 295 · Phase 2 303 · Phase 3 54 · Phase 4 3
First in 1991; this study’s year is marked. 33 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 491 is above the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.
Median enrollment 55 across the 550 interventional studies, 111 across the 51 observational. Of the 417 that completed or were terminated, 173 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
294 of 629 have an industry lead sponsor. The 10 most frequent:
Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
Ipsen has 4 studies filed under Small Cell Lung Carcinoma — fewer than ten, so there is no comparison to draw.
44 of the studies in Small Cell Lung Carcinoma with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01064466Phase 3Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB ChairPharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms | 2026-11-18 |
| NCT06646276Phase 3Bristol-Myers SquibbA Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). | 2027-08-17 |
| NCT07778316Phase 3AmgenPhase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) | 2027-09-24 |
| NCT04624204Phase 3Merck Sharp & Dohme LLCPlacebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) | 2027-10-28 |
| NCT07473128Phase 3Pharmacosmos A/SEffect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer | 2027-10-31 |
Add all 44 to your calendar (.ics) → With an account.
Among the 629 studies in Small Cell Lung Carcinoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A randomized, open label phase 3 study of irinotecan liposome injection (ONIVYDE®) versus topotecan in patients with small cell lung cancer who have progressed on or after platinum-based first-line therapy
The study was conducted in two parts:
The study was conducted in two parts:
Part 1: Open-label dose-finding study of irinotecan liposome injection. 30 patients were planned to be enrolled.
Part 1 Primary Objectives:
Part 2: A randomized, efficacy study of irinotecan liposome injection versus intravenous (IV) topotecan.
Approximately 450 patients were planned to be enrolled in part 2.
Part 2 objectives: To compare overall survival following treatment with irinotecan liposome injection with overall survival following treatment with IV topotecan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with certain types of asymptomatic that meet ALL the following criteria are eligible.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Irinotecan liposome injection
Drug: Irinotecan liposome injection
Irinotecan liposome injection
Drug: Irinotecan liposome injection
Irinotecan liposome injection
Drug: Irinotecan liposome injection
Topotecan
Drug: Topotecan
IV
Also known as: ONIVYDE®
IV
Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)
An adverse event (AE) was any untoward medical occurrence in a participant following or during exposure to a study treatment, whether or not causally related to the study treatment. An undesirable medical condition could be symptoms, signs or abnormal results of an investigation. An SAE was any AE that: resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability or incapacity; resulted in congenital anomaly or birth defect; or was medically important. A TEAE was any AE that occurred or worsened on or after the day of first dose of study treatment and within 30 days after discontinuation of study treatment.
Time frame: The TEAEs were reported from the time of first study treatment administration (Day 1) up to 30 days after the date of last study treatment administration, approximately 680 days
Part 1: Number of Participants With Dose-Limiting Toxicities (DLT)
A TEAE was considered as DLT if it occurred during the safety evaluation period (i.e. first 28 days of treatment or 14 days after the second dose of study treatment if there was a treatment delay due to non-DLT related reasons) and were deemed related to the study treatment by the investigator. The determination of whether an Adverse Event was considered a Dose Limiting Toxicity was made by the Safety Review Committee (SRC) comprising the Part 1 Investigators and the Medical Monitor(s) of the Sponsor.
Time frame: From the start of the first study treatment administration (Day 1) up to 14 days after the second dose of study treatment administration, a maximum of 42 days
Part 2: Overall Survival (OS)
The OS was defined as the time from randomization date to the date of death from any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. The OS was calculated using Kaplan-Meier technique. Following end of treatment participant and/or family was contacted by telephone every month to assess vital status.
Time frame: From date of randomization (within 7 days before start of study treatment) until death. Assessed up to Part 2 primary analysis DCO date of 08 February 2022 (approximately 900 days)
Part 1: Objective Response Rate (ORR)
The ORR was defined as the percentage of participants with a best overall response (BOR) characterized as either a complete response (CR) or partial response (PR) recorded from date of first dose of study treatment until documented PD or death. ORR analysis was based on BOR using RECIST v1.1 per investigator assessment. Per RECIST v1.1, CR is disappearance of all target lesions; PR is \>=30% decrease in the sum of the longest diameter of target lesions; and overall response = CR + PR. Per protocol, participants had computed tomography (CT)-scans and brain magnetic resonance imaging (MRI) every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.
Time frame: RECIST assessments performed at Baseline (within 28 days before start of study treatment), every 6 weeks post first dose and treatment pause, 30 days after discontinuation of study treatment, then every month thereafter, approximately maximum of 1177 days
Part 1: Progression-Free Survival (PFS)
The PFS was defined as time from first dose of study treatment to the first documented objective PD using RECIST v1.1 or death due to any cause, whichever occurs first. Per RECIST 1.1, progression is defined as at least 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The PFS was calculated using Kaplan-Meier technique. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.
Time frame: RECIST assessments performed at Baseline (within 28 days before start of study treatment), every 6 weeks post first dose and treatment pause, 30 days after discontinuation of study treatment, then every month thereafter, approximately maximum of 1177 days
Part 1: OS
The OS was defined as the time from first dose of study treatment to the date of death from any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. The OS was calculated using Kaplan-Meier technique. Following end of treatment participant and/or family was contacted by telephone every month to assess vital status.
Time frame: From Baseline (Day 1) until death. Assessed up to Part 1 DCO date of 11 August 2021 (approximately 1177 days)
Part 2: PFS
The PFS was defined as time from randomization to first documented objective PD using RECIST 1.1 (or response assessment in neuro-oncology brain metastases \[RANO-BM\] criteria for central nervous system \[CNS\] lesions) as assessed by blinded independent central review (BICR) or death due to any cause, whichever occurred first. Per RECIST 1.1, progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The PFS was calculated using Kaplan-Meier technique. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.
Time frame: RECIST assessments performed at Baseline (within 28 days before start of study treatment), every 6 weeks post first dose and treatment pause, 30 days after discontinuation of study treatment, then every month thereafter, approximately maximum of 900 days
Part 2: ORR
The ORR was defined as percentage of participants with a BOR characterized as either a CR or PR, recorded from randomization until documented PD or death relative to the total number of participants. ORR analysis was based on BOR assessed by BICR using RECIST v1.1. Per RECIST v1.1, CR is disappearance of all target lesions; PR is \>=30% decrease in the sum of the longest diameter of target lesions; and overall response = CR + PR. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.
Time frame: RECIST assessments performed at Baseline (within 28 days before start of study treatment), every 6 weeks post first dose and treatment pause, 30 days after discontinuation of study treatment, then every month thereafter, approximately maximum of 900 days
Part 2: Median Duration of Response (DoR)
The DoR was defined as time from the first documented objective response (CR or PR, whichever was earlier) to the date of first documented PD or death due to any cause. The DoR analysis was based on BOR assessed by BICR using RECIST v1.1. Per RECIST v1.1, CR is disappearance of all target lesions and PR is \>=30% decrease in the sum of the longest diameter of target lesions. The DoR was calculated using Kaplan-Meier technique. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.
Time frame: RECIST assessments performed at Baseline (within 28 days before start of study treatment), every 6 weeks post first dose and treatment pause, 30 days after discontinuation of study treatment, then every month thereafter, approximately maximum of 900 days
Part 2: Median Time to Objective Response (OR)
Time to OR as per RECIST v1.1 criteria according to BICR was defined as time from the date of randomization to the date of first documented objective tumor response (CR or PR, whichever was first). Per RECIST v1.1, CR is disappearance of all target lesions; PR is \>=30% decrease in the sum of the longest diameter of target lesion. Participants with a new anti-cancer therapy prior to OR were censored at the last tumor assessment prior to new anti-cancer therapy. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.
Time frame: RECIST assessments performed at Baseline (within 28 days before start of study treatment), every 6 weeks post first dose and treatment pause, 30 days after discontinuation of study treatment, then every month thereafter, approximately maximum of 900 days
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30)/Lung Cancer Supplement (LC13) Dyspnea Scale at Week 12
The EORTC QLQ-LC13 is a lung cancer specific module used in conjunction with EORTC QLQ-C30 and covers typical symptoms of lung cancer (cough, pain, dyspnea, sore mouth, peripheral neuropathy, hair loss). Scores range from 0-100 and a high score represents a high level of symptomatology/problems/worse QoL. Baseline was defined as the last non-missing measurement taken prior to reference start date. Change from baseline in dyspnea scale was calculated regardless of premature study treatment discontinuation. Participants completed these questionnaires on an electronic tablet every 6 weeks during treatment and it was continued until PD or commencement of new anti-neoplastic therapy.
Time frame: Baseline (Day 1) and Week 12
Change From Baseline in EORTC QLQ-LC13 Cough Scale at Week 12
The EORTC QLQ-LC13 is a lung cancer specific module used in conjunction with EORTC QLQ-C30 and covers typical symptoms of lung cancer (cough, pain, dyspnea, sore mouth, peripheral neuropathy, hair loss). Score ranges from 0-100 scale and a high score represents a high level of symptomatology/problems/worse QoL. Baseline was defined as the last non-missing measurement taken prior to reference start date. Change from baseline in cough scale was calculated regardless of premature study treatment discontinuation. Participants completed these questionnaires on an electronic tablet every 6 weeks during treatment and it was continued until PD or commencement of new anti-neoplastic therapy.
Time frame: Baseline (Day 1) and Week 12
This Phase III, 2-part (Part 1: \[open-label, single-arm dose evaluation period\] and Part 2 \[randomized, open-label period\]) study was conducted in participants with small cell lung cancer (SCLC) who progressed on or after platinum-based first-line therapy at 11 sites for Part 1 and 116 sites for Part 2 in the USA, Europe, Asia, Australia, Turkey and Brazil. First participant was enrolled on 25 April 2018 and primary analysis data cut-off (DCO) date was 08 February 2022 for Part 2.
| Milestone | Part 1: Irinotecan Liposome Injection 85 Milligrams/Meter Square (mg/m^2) | Part 1: Irinotecan Liposome Injection 70 mg/m^2 | Part 2: Irinotecan Liposome Injection 70 mg/m^2 | Part 2: Topotecan 1.5 mg/m^2 |
|---|---|---|---|---|
| Started | 5 | 25 | 0 | 0 |
| Completed | 5 | 24 | 0 | 0 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Milestone | Part 1: Irinotecan Liposome Injection 85 Milligrams/Meter Square (mg/m^2) | Part 1: Irinotecan Liposome Injection 70 mg/m^2 | Part 2: Irinotecan Liposome Injection 70 mg/m^2 | Part 2: Topotecan 1.5 mg/m^2 |
|---|---|---|---|---|
| Started | 0 | 0 | 229 | 232 |
| Completed | 0 | 0 | 202 | 211 |
| Not completed | 0 | 0 | 27 | 21 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 |
| Withdrew: Investigator decision | 0 | 0 | 2 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 3 | 4 |
| Withdrew: Withdrawal by subject | 0 | 0 | 18 | 14 |
| Withdrew: Screen failure | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 3 | 0 |
An adverse event (AE) was any untoward medical occurrence in a participant following or during exposure to a study treatment, whether or not causally related to the study treatment. An undesirable medical condition could be symptoms, signs or abnormal results of an investigation. An SAE was any AE that: resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability or incapacity; resulted in congenital anomaly or birth defect; or was medically important. A TEAE was any AE that occurred or worsened on or after the day of first dose of study treatment and within 30 days after discontinuation of study treatment.
| Participants | Part 1: Irinotecan Liposome Injection 85 mg/m^2 | Part 1: Irinotecan Liposome Injection 70 mg/m^2 |
|---|---|---|
| Any TEAE | 5 | 25 |
| Serious TEAEs | 4 | 9 |
A TEAE was considered as DLT if it occurred during the safety evaluation period (i.e. first 28 days of treatment or 14 days after the second dose of study treatment if there was a treatment delay due to non-DLT related reasons) and were deemed related to the study treatment by the investigator. The determination of whether an Adverse Event was considered a Dose Limiting Toxicity was made by the Safety Review Committee (SRC) comprising the Part 1 Investigators and the Medical Monitor(s) of the Sponsor.
| Participants | Part 1: Irinotecan Liposome Injection 85 mg/m^2 | Part 1: Irinotecan Liposome Injection 70 mg/m^2 |
|---|---|---|
| Part 1: Number of Participants With Dose-Limiting Toxicities (DLT) | 4 | 2 |
The OS was defined as the time from randomization date to the date of death from any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. The OS was calculated using Kaplan-Meier technique. Following end of treatment participant and/or family was contacted by telephone every month to assess vital status.
| months | Part 2: Irinotecan Liposome Injection 70 mg/m^2 | Part 2: Topotecan 1.5 mg/m^2 |
|---|---|---|
| Part 2: Overall Survival (OS) | 7.92 (6.87 to 9.23) | 8.31 (7.33 to 9.13) |
The ORR was defined as the percentage of participants with a best overall response (BOR) characterized as either a complete response (CR) or partial response (PR) recorded from date of first dose of study treatment until documented PD or death. ORR analysis was based on BOR using RECIST v1.1 per investigator assessment. Per RECIST v1.1, CR is disappearance of all target lesions; PR is \>=30% decrease in the sum of the longest diameter of target lesions; and overall response = CR + PR. Per protocol, participants had computed tomography (CT)-scans and brain magnetic resonance imaging (MRI) every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.
| percentage of participants | Part 1: Irinotecan Liposome Injection 85 mg/m^2 | Part 1: Irinotecan Liposome Injection 70 mg/m^2 |
|---|---|---|
| Part 1: Objective Response Rate (ORR) | 40 (5.27 to 85.34) | 44 (24.40 to 65.07) |
The PFS was defined as time from first dose of study treatment to the first documented objective PD using RECIST v1.1 or death due to any cause, whichever occurs first. Per RECIST 1.1, progression is defined as at least 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The PFS was calculated using Kaplan-Meier technique. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.
| months | Part 1: Irinotecan Liposome Injection 85 mg/m^2 | Part 1: Irinotecan Liposome Injection 70 mg/m^2 |
|---|---|---|
| Part 1: Progression-Free Survival (PFS) | 4.19 (1.58 to NA) | 3.98 (2.69 to 4.24) |
The OS was defined as the time from first dose of study treatment to the date of death from any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. The OS was calculated using Kaplan-Meier technique. Following end of treatment participant and/or family was contacted by telephone every month to assess vital status.
| months | Part 1: Irinotecan Liposome Injection 85 mg/m^2 | Part 1: Irinotecan Liposome Injection 70 mg/m^2 |
|---|---|---|
| Part 1: OS | 10.84 (0.99 to NA) | 8.08 (5.16 to 9.82) |
The PFS was defined as time from randomization to first documented objective PD using RECIST 1.1 (or response assessment in neuro-oncology brain metastases \[RANO-BM\] criteria for central nervous system \[CNS\] lesions) as assessed by blinded independent central review (BICR) or death due to any cause, whichever occurred first. Per RECIST 1.1, progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The PFS was calculated using Kaplan-Meier technique. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.
| months | Part 2: Irinotecan Liposome Injection 70 mg/m^2 | Part 2: Topotecan 1.5 mg/m^2 |
|---|---|---|
| Part 2: PFS | 4.01 (2.96 to 4.17) | 3.25 (2.79 to 4.14) |
The ORR was defined as percentage of participants with a BOR characterized as either a CR or PR, recorded from randomization until documented PD or death relative to the total number of participants. ORR analysis was based on BOR assessed by BICR using RECIST v1.1. Per RECIST v1.1, CR is disappearance of all target lesions; PR is \>=30% decrease in the sum of the longest diameter of target lesions; and overall response = CR + PR. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.
| percentage of participants | Part 2: Irinotecan Liposome Injection 70 mg/m^2 | Part 2: Topotecan 1.5 mg/m^2 |
|---|---|---|
| Part 2: ORR | 44.1 (37.57 to 50.79) | 21.6 (16.44 to 27.41) |
The DoR was defined as time from the first documented objective response (CR or PR, whichever was earlier) to the date of first documented PD or death due to any cause. The DoR analysis was based on BOR assessed by BICR using RECIST v1.1. Per RECIST v1.1, CR is disappearance of all target lesions and PR is \>=30% decrease in the sum of the longest diameter of target lesions. The DoR was calculated using Kaplan-Meier technique. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.
| months | Part 2: Irinotecan Liposome Injection 70 mg/m^2 | Part 2: Topotecan 1.5 mg/m2 IV |
|---|---|---|
| Part 2: Median Duration of Response (DoR) | 4.14 (3.06 to 4.34) | 4.17 (2.86 to 4.76) |
Time to OR as per RECIST v1.1 criteria according to BICR was defined as time from the date of randomization to the date of first documented objective tumor response (CR or PR, whichever was first). Per RECIST v1.1, CR is disappearance of all target lesions; PR is \>=30% decrease in the sum of the longest diameter of target lesion. Participants with a new anti-cancer therapy prior to OR were censored at the last tumor assessment prior to new anti-cancer therapy. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.
| months | Part 2: Irinotecan Liposome Injection 70 mg/m^2 | Part 2: Topotecan 1.5 mg/m^2 |
|---|---|---|
| Part 2: Median Time to Objective Response (OR) | 1.68 (1.51 to 4.11) | 12.65 (8.41 to NA) |
The EORTC QLQ-LC13 is a lung cancer specific module used in conjunction with EORTC QLQ-C30 and covers typical symptoms of lung cancer (cough, pain, dyspnea, sore mouth, peripheral neuropathy, hair loss). Scores range from 0-100 and a high score represents a high level of symptomatology/problems/worse QoL. Baseline was defined as the last non-missing measurement taken prior to reference start date. Change from baseline in dyspnea scale was calculated regardless of premature study treatment discontinuation. Participants completed these questionnaires on an electronic tablet every 6 weeks during treatment and it was continued until PD or commencement of new anti-neoplastic therapy.
| scores on a scale | Part 2: Irinotecan Liposome Injection 70 mg/m^2 | Part 2: Topotecan 1.5 mg/m^2 |
|---|---|---|
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30)/Lung Cancer Supplement (LC13) Dyspnea Scale at Week 12 | 4.6 ± 20.74 | 1.9 ± 19.17 |
The EORTC QLQ-LC13 is a lung cancer specific module used in conjunction with EORTC QLQ-C30 and covers typical symptoms of lung cancer (cough, pain, dyspnea, sore mouth, peripheral neuropathy, hair loss). Score ranges from 0-100 scale and a high score represents a high level of symptomatology/problems/worse QoL. Baseline was defined as the last non-missing measurement taken prior to reference start date. Change from baseline in cough scale was calculated regardless of premature study treatment discontinuation. Participants completed these questionnaires on an electronic tablet every 6 weeks during treatment and it was continued until PD or commencement of new anti-neoplastic therapy.
| scores on a scale | Part 2: Irinotecan Liposome Injection 70 mg/m^2 | Part 2: Topotecan 1.5 mg/m^2 |
|---|---|---|
| Change From Baseline in EORTC QLQ-LC13 Cough Scale at Week 12 | 1.6 ± 25.77 | -1.2 ± 27.31 |
Collected over The TEAEs were reported from the time of first study treatment administration (Day 1) up to 30 days after the date of last study treatment administration, approximately 680 days for Part 1 and 1452 days for Part 2. All-Cause Mortality: approximately 1919 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Irinotecan Liposome Injection 85 mg/m^2 | 5/5 (100%) | 4/5 (80%) | 5/5 (100%) |
| Part 1: Irinotecan Liposome Injection 70 mg/m^2 | 23/25 (92%) | 9/25 (36%) | 25/25 (100%) |
| Part 2: Irinotecan Liposome Injection 70 mg/m^2 | 201/226 (88.9%) | 106/226 (46.9%) | 212/226 (93.8%) |
| Part 2: Topotecan 1.5 mg/m^2 | 205/223 (91.9%) | 88/223 (39.5%) | 220/223 (98.7%) |
| Event | Part 1: Irinotecan Liposome Injection 85 mg/m^2 | Part 1: Irinotecan Liposome Injection 70 mg/m^2 | Part 2: Irinotecan Liposome Injection 70 mg/m^2 | Part 2: Topotecan 1.5 mg/m^2 |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 2/5 | 2/25 | 16/226 | 7/223 |
| Cardiac arrestCardiac disorders | 1/5 | 0/25 | 0/226 | 0/223 |
| Ectopic antidiuretic hormone secretionEndocrine disorders | 1/5 | 0/25 | 0/226 | 0/223 |
| DiarrhoeaGastrointestinal disorders | 1/5 | 1/25 | 19/226 | 1/223 |
| NauseaGastrointestinal disorders | 1/5 | 0/25 | 2/226 | 3/223 |
| VomitingGastrointestinal disorders | 1/5 | 0/25 | 3/226 | 3/223 |
| HepatotoxicityHepatobiliary disorders | 1/5 | 0/25 | 0/226 | 0/223 |
| Liver function test abnormalInvestigations | 1/5 | 0/25 | 0/226 | 0/223 |
| HyponatraemiaMetabolism and nutrition disorders | 1/5 | 0/25 | 1/226 | 5/223 |
| Superior vena cava syndromeVascular disorders | 1/5 | 0/25 | 0/226 | 1/223 |
| Event | Part 1: Irinotecan Liposome Injection 85 mg/m^2 | Part 1: Irinotecan Liposome Injection 70 mg/m^2 | Part 2: Irinotecan Liposome Injection 70 mg/m^2 | Part 2: Topotecan 1.5 mg/m^2 |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 5/5 | 22/25 | 128/226 | 43/223 |
| Decreased appetiteMetabolism and nutrition disorders | 4/5 | 10/25 | 81/226 | 43/223 |
| AnaemiaBlood and lymphatic system disorders | 2/5 | 7/25 | 82/226 | 177/223 |
| NeutropeniaBlood and lymphatic system disorders | 3/5 | 4/25 | 41/226 | 137/223 |
| NauseaGastrointestinal disorders | 3/5 | 11/25 | 96/226 | 58/223 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/5 | 1/25 | 11/226 | 16/223 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/5 | 4/25 | 11/226 | 131/223 |
| LeukopeniaBlood and lymphatic system disorders | 0/5 | 0/25 | 29/226 | 94/223 |
| Abdominal painGastrointestinal disorders | 2/5 | 5/25 | 41/226 | 8/223 |
| ConstipationGastrointestinal disorders | 2/5 | 3/25 | 29/226 | 35/223 |
Part 1: Safety population included all enrolled participants who were treated with at least 1 dose of irinotecan liposome injection. Part 2: Intent-to-Treat (ITT) population included all randomized participants.
| Age, Customized(Participants) | Part 1: Irinotecan Liposome Injection 85 mg/m^2 | Part 1: Irinotecan Liposome Injection 70 mg/m^2 | Part 2: Irinotecan Liposome Injection 70 mg/m^2 | Part 2: Topotecan 1.5 mg/m^2 | Total |
|---|---|---|---|---|---|
| <65 years | 4 | 18 | 128 | 151 | 301 |
| >=65 years | 1 | 7 | 101 | 81 | 190 |
| Sex: Female, Male(Participants) | Part 1: Irinotecan Liposome Injection 85 mg/m^2 | Part 1: Irinotecan Liposome Injection 70 mg/m^2 | Part 2: Irinotecan Liposome Injection 70 mg/m^2 | Part 2: Topotecan 1.5 mg/m^2 | Total |
|---|---|---|---|---|---|
| Female | 2 | 16 | 79 | 69 | 166 |
| Male | 3 | 9 | 150 | 163 | 325 |
| Race/Ethnicity, Customized(Participants) | Part 1: Irinotecan Liposome Injection 85 mg/m^2 | Part 1: Irinotecan Liposome Injection 70 mg/m^2 | Part 2: Irinotecan Liposome Injection 70 mg/m^2 | Part 2: Topotecan 1.5 mg/m^2 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 |
| Asian | 0 | 0 | 37 | 36 | 73 |
| Black or African American | 0 | 0 | 4 | 4 | 8 |
| White | 5 | 25 | 184 | 182 | 396 |
| Not Reported | 0 | 0 | 4 | 9 | 13 |
| Race/Ethnicity, Customized(Participants) | Part 1: Irinotecan Liposome Injection 85 mg/m^2 | Part 1: Irinotecan Liposome Injection 70 mg/m^2 | Part 2: Irinotecan Liposome Injection 70 mg/m^2 | Part 2: Topotecan 1.5 mg/m^2 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 6 | 9 | 17 |
| Not Hispanic or Latino | 5 | 20 | 214 | 218 | 457 |
| Not Reported/Unknown | 0 | 3 | 9 | 5 | 17 |
Showing the first 100 of 118 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2018 to primary completion in Feb 2022, 45 months.
Results were first posted in Oct 2023, 1 year 8 months after primary completion. A results delay was requested in Jan 2023.
Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's 45 months is above that.
Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Irinotecan sucrosofate